What is the projected market valuation for the Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Industry by 2035?

The projected market valuation for 2035 is 6.493 USD Billion. Read More

What was the overall market valuation in 2024 for this industry?

The overall market valuation was 4.49 USD Billion in 2024. Read More

What is the expected CAGR for the market during the forecast period of 2025 - 2035?

The expected CAGR for the market during the forecast period 2025 - 2035 is 3.41%. Read More

Which companies are considered key players in the Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Industry?

Key players include Elekta AB, Varian Medical Systems, Brachytherapy Solutions, and others. Read More

What segment had the highest valuation in 2024 within the application category?

In 2024, the Oncology segment had the highest valuation at 1.5 USD Billion. Read More

How much is the Cardiology segment projected to grow by 2035?

The Cardiology segment is projected to grow from 0.8 USD Billion in 2024 to 1.1 USD Billion by 2035. Read More

What is the projected valuation for the Beta Emitters segment by 2035?

The Beta Emitters segment is projected to reach 2.5 USD Billion by 2035. Read More

Which end-use segment is expected to show the most growth from 2024 to 2035?

The Diagnostic Centers segment is expected to grow from 1.54 USD Billion in 2024 to 2.39 USD Billion by 2035. Read More

What is the projected growth for the Liquid radiopharmaceutical formulation segment by 2035?

The Liquid radiopharmaceutical formulation segment is projected to grow from 1.8 USD Billion in 2024 to 2.5 USD Billion by 2035. Read More

How does the market for Combined Emitters compare to Alpha and Beta Emitters by 2035?

By 2035, the market for Combined Emitters is projected at 1.89 USD Billion, which is lower than both Alpha Emitters at 2.1 USD Billion and Beta Emitters at 2.5 USD Billion. Read More

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market Research Report: Size, Share, Trend Analysis By Applications (Oncology, Cardiology, Neurology, Orthopedics, Palliative Care), By Types (Alpha Emitters, Beta Emitters, Combined Emitters), By End Use (Hospitals, Ambulatory Surgical Centers, Research Institutes, Diagnostic Centers), By Radiopharmaceutical Formulation (Solid, Liquid, Gas) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.41%

2024 Market Size

$ 4.49

2035 Market Size

$ 6.49

Pharmaceutical ● Updated August 2026 Report ID: MRFR/Pharma/41509-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Orthopedics
  5. 4.1.5 Palliative Care
2. 4.2 Healthcare, BY Type (USD Billion)
  1. 4.2.1 Alpha Emitters
  2. 4.2.2 Beta Emitters
  3. 4.2.3 Combined Emitters
3. 4.3 Healthcare, BY End Use (USD Billion)
  1. 4.3.1 Hospitals
  2. 4.3.2 Ambulatory Surgical Centers
  3. 4.3.3 Research Institutes
  4. 4.3.4 Diagnostic Centers
4. 4.4 Healthcare, BY Radiopharmaceutical Formulation (USD Billion)
  1. 4.4.1 Solid
  2. 4.4.2 Liquid
  3. 4.4.3 Gas
5. 4.5 Healthcare, BY Region (USD Billion)
  1. 4.5.1 North America
    1. 4.5.1.1 US
    2. 4.5.1.2 Canada
  2. 4.5.2 Europe
    1. 4.5.2.1 Germany
    2. 4.5.2.2 UK
    3. 4.5.2.3 France
    4. 4.5.2.4 Russia
    5. 4.5.2.5 Italy
    6. 4.5.2.6 Spain
    7. 4.5.2.7 Rest of Europe
  3. 4.5.3 APAC
    1. 4.5.3.1 China
    2. 4.5.3.2 India
    3. 4.5.3.3 Japan
    4. 4.5.3.4 South Korea
    5. 4.5.3.5 Malaysia
    6. 4.5.3.6 Thailand
    7. 4.5.3.7 Indonesia
    8. 4.5.3.8 Rest of APAC
  4. 4.5.4 South America
    1. 4.5.4.1 Brazil
    2. 4.5.4.2 Mexico
    3. 4.5.4.3 Argentina
    4. 4.5.4.4 Rest of South America
  5. 4.5.5 MEA
    1. 4.5.5.1 GCC Countries
    2. 4.5.5.2 South Africa
    3. 4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Elekta AB (SE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Varian Medical Systems (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Brachytherapy Solutions (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 CIVCO Medical Solutions (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Nucletron (NL)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 IsoRay Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Theragenics Corporation (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Sordina IORT Technologies (IT)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 MDS Nordion (CA)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY TYPE
5. 6.5 US MARKET ANALYSIS BY END USE
6. 6.6 US MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
7. 6.7 CANADA MARKET ANALYSIS BY APPLICATION
8. 6.8 CANADA MARKET ANALYSIS BY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY END USE
10. 6.10 CANADA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
11. 6.11 EUROPE MARKET ANALYSIS
12. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION
13. 6.13 GERMANY MARKET ANALYSIS BY TYPE
14. 6.14 GERMANY MARKET ANALYSIS BY END USE
15. 6.15 GERMANY MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
16. 6.16 UK MARKET ANALYSIS BY APPLICATION
17. 6.17 UK MARKET ANALYSIS BY TYPE
18. 6.18 UK MARKET ANALYSIS BY END USE
19. 6.19 UK MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
20. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION
21. 6.21 FRANCE MARKET ANALYSIS BY TYPE
22. 6.22 FRANCE MARKET ANALYSIS BY END USE
23. 6.23 FRANCE MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
24. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION
25. 6.25 RUSSIA MARKET ANALYSIS BY TYPE
26. 6.26 RUSSIA MARKET ANALYSIS BY END USE
27. 6.27 RUSSIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
28. 6.28 ITALY MARKET ANALYSIS BY APPLICATION
29. 6.29 ITALY MARKET ANALYSIS BY TYPE
30. 6.30 ITALY MARKET ANALYSIS BY END USE
31. 6.31 ITALY MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
32. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION
33. 6.33 SPAIN MARKET ANALYSIS BY TYPE
34. 6.34 SPAIN MARKET ANALYSIS BY END USE
35. 6.35 SPAIN MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
36. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
37. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE
38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE
39. 6.39 REST OF EUROPE MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
40. 6.40 APAC MARKET ANALYSIS
41. 6.41 CHINA MARKET ANALYSIS BY APPLICATION
42. 6.42 CHINA MARKET ANALYSIS BY TYPE
43. 6.43 CHINA MARKET ANALYSIS BY END USE
44. 6.44 CHINA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
45. 6.45 INDIA MARKET ANALYSIS BY APPLICATION
46. 6.46 INDIA MARKET ANALYSIS BY TYPE
47. 6.47 INDIA MARKET ANALYSIS BY END USE
48. 6.48 INDIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
49. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION
50. 6.50 JAPAN MARKET ANALYSIS BY TYPE
51. 6.51 JAPAN MARKET ANALYSIS BY END USE
52. 6.52 JAPAN MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
53. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
54. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE
55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE
56. 6.56 SOUTH KOREA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
57. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION
58. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE
59. 6.59 MALAYSIA MARKET ANALYSIS BY END USE
60. 6.60 MALAYSIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
61. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION
62. 6.62 THAILAND MARKET ANALYSIS BY TYPE
63. 6.63 THAILAND MARKET ANALYSIS BY END USE
64. 6.64 THAILAND MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
65. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION
66. 6.66 INDONESIA MARKET ANALYSIS BY TYPE
67. 6.67 INDONESIA MARKET ANALYSIS BY END USE
68. 6.68 INDONESIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
69. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION
70. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE
71. 6.71 REST OF APAC MARKET ANALYSIS BY END USE
72. 6.72 REST OF APAC MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
73. 6.73 SOUTH AMERICA MARKET ANALYSIS
74. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION
75. 6.75 BRAZIL MARKET ANALYSIS BY TYPE
76. 6.76 BRAZIL MARKET ANALYSIS BY END USE
77. 6.77 BRAZIL MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
78. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION
79. 6.79 MEXICO MARKET ANALYSIS BY TYPE
80. 6.80 MEXICO MARKET ANALYSIS BY END USE
81. 6.81 MEXICO MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
82. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION
83. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE
84. 6.84 ARGENTINA MARKET ANALYSIS BY END USE
85. 6.85 ARGENTINA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
90. 6.90 MEA MARKET ANALYSIS
91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE
93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE
94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE
97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE
98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
99. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION
100. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE
101. 6.101 REST OF MEA MARKET ANALYSIS BY END USE
102. 6.102 REST OF MEA MARKET ANALYSIS BY RADIOPHARMACEUTICAL FORMULATION
103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
104. 6.104 RESEARCH PROCESS OF MRFR
105. 6.105 DRO ANALYSIS OF HEALTHCARE
106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
109. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
110. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
111. 6.111 HEALTHCARE, BY TYPE, 2024 (% SHARE)
112. 6.112 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
113. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE)
114. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
115. 6.115 HEALTHCARE, BY RADIOPHARMACEUTICAL FORMULATION, 2024 (% SHARE)
116. 6.116 HEALTHCARE, BY RADIOPHARMACEUTICAL FORMULATION, 2024 TO 2035 (USD Billion)
117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.2.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.3.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.3.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.4.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.4.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.5.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.5.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.6.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.6.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.7.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.7.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.8.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.8.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.9.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.9.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.10.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.10.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.11.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.11.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.12.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.12.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.13.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.13.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.14.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.14.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.15.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.15.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.16.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.16.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.17.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.17.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.18.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.18.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.19.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.19.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.20.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.20.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.21.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.21.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.22.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.22.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.23.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.23.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.24.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.24.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.25.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.25.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.26.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.26.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.27.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.27.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.28.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.28.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.29.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.29.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion)
  2. 7.30.2 BY TYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY END USE, 2025-2035 (USD Billion)
  4. 7.30.4 BY RADIOPHARMACEUTICAL FORMULATION, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market Segmentation

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market By Application (USD Billion, 2025-2035)

Oncology
Cardiology
Neurology
Orthopedics
Palliative Care

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market By Type (USD Billion, 2025-2035)

Alpha Emitters
Beta Emitters
Combined Emitters

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market By End Use (USD Billion, 2025-2035)

Hospitals
Ambulatory Surgical Centers
Research Institutes
Diagnostic Centers

Nuclear Medicine Therapeutic Alpha Beta Emitters Brachytherapy Market By Radiopharmaceutical Formulation (USD Billion, 2025-2035)

Solid
Liquid
Gas

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035